Clinical Course of Oxaliplatin-Induced Neuropathy: Results From the Randomized Phase III Trial N08CB (Alliance).
about
Optimizing adjuvant therapy and survivorship care of stage III colon cancer.Effects of transcutaneous electrical nerve stimulation on chemotherapy-induced peripheral neuropathy symptoms (CIPN): a preliminary case-control study.Comparison of oxaliplatin and paclitaxel-induced neuropathy (Alliance A151505).Herbal Medicine AC591 Prevents Oxaliplatin-Induced Peripheral Neuropathy in Animal Model and Cancer Patients.A phosphotyrosine switch regulates organic cation transporters.Adjuvant FOLFOX treatment for stage III colon cancer: how many cycles are enough?Inhibition of α9α10 nicotinic acetylcholine receptors prevents chemotherapy-induced neuropathic pain.Factors associated with the development and severity of oxaliplatin-induced peripheral neuropathy: a systematic review.Chemotherapy-induced peripheral neuropathy: A current review.Chronic Oxaliplatin-Based Chemotherapy in a Primary Ampullary Adenocarcinoma Patient without Significant Peripheral Neuropathy: Case Report and Literature Review.Inflammatory Response and Toxicity After Pressurized IntraPeritoneal Aerosol Chemotherapy.Efficacy of a Novel Sigma-1 Receptor Antagonist for Oxaliplatin-Induced Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase IIa Clinical Trial.Pharmacokinetic and toxicodynamic evaluation of oxaliplatin-induced neuropathy and hematological toxicity in rats.Oxaliplatin added to fluoropyrimidine for adjuvant treatment of colorectal cancer is associated with long-term impairment of peripheral nerve sensory function and quality of life.Multimodal quantitative examination of nerve function in colorectal cancer patients prior to chemotherapy.Pain in Platin-Induced Neuropathies: A Systematic Review and Meta-Analysis.A rat model of FOLFOX-induced neuropathy: effects of oral dimiracetam in comparison with duloxetine and pregabalin.Oxaliplatin-induced Peripheral Neuropathy in South Indian Cancer Patients: A Prospective Study in Digestive Tract Cancer Patients.Rehabilitation of Cancer Survivors with Long-Term Toxicities.Persistent prevention of oxaliplatin-induced peripheral neuropathy using calmangafodipir (PledOx®): a placebo-controlled randomised phase II study (PLIANT).Evaluation of the treatment of chronic chemotherapy-induced peripheral neuropathy using long-wave diathermy and interferential currents: a randomized controlled trial.Eight-week, multimodal exercise counteracts a progress of chemotherapy-induced peripheral neuropathy and improves balance and strength in metastasized colorectal cancer patients: a randomized controlled trial.The incidence of acute oxaliplatin-induced neuropathy and its impact on treatment in the first cycle: a systematic review.3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial.Hyperacute peripheral neuropathy is a predictor of oxaliplatin-induced persistent peripheral neuropathy.Phase I study of neoadjuvant chemotherapy with S-1 and oxaliplatin for locally advanced gastric cancer (Neo G-SOX PI).Gaps in Understanding Mechanism and Lack of Treatments: Potential Use of a Nonhuman Primate Model of Oxaliplatin-Induced Neuropathic Pain.
P2860
Q30249616-BCB7BED9-DBDD-4B65-8EA8-92B2E8954AB2Q33680116-5C60B302-5AFB-4213-AC20-AD96C7244F21Q33711444-65A8088B-CE63-4832-8551-B2B18EE2F272Q33770708-BCF23228-9140-4CCA-B51F-8113D6B61100Q36704820-011E85E4-3606-40F5-A835-3A089A215894Q37167151-6D86F5D0-A497-47AB-90AD-6E3523C518D3Q37695948-44285309-A0D5-4A12-9C6B-D9C71E96763CQ38707400-8D48374A-D66D-4A4B-9C48-4C5DF9AF9286Q39293928-D014355B-A9F5-45A7-B346-D620ECF03751Q41488055-DDB9830A-CC15-402C-A7F3-1992CEB9C407Q47109168-39C7F1B0-5AF0-47F1-A00E-5461A9819E87Q47266458-D718833F-81EF-4C35-B1B2-6B74D812F099Q47430728-349DC944-0916-4E41-9DDB-10974AB839FCQ47670602-BA8BC64E-752E-451D-985A-D01DF23A7572Q48020601-0F58000A-E0B5-499D-BF0E-E8943474FF26Q48192466-073FAF97-C16D-4677-B510-B5E8497B9516Q48194389-CDB0B49A-14D2-4120-A09B-1C9801E14BE7Q49439093-F24E0AF9-578F-4041-879C-CD97A473AFDFQ49572401-832DEB66-645B-4294-AA1A-90208E067BEBQ50002199-FC3D51D6-35A4-4C93-8F7E-7B1EA8BFE071Q50250068-ED46A022-3905-48E9-9A15-59ABE950834DQ50269461-601DC344-CAFB-4964-9074-1BDECAE84530Q52591422-4757DDC2-8B24-4EE0-9FEC-6CBF384377D4Q52610762-950A059E-D084-4C65-B226-453F7532F6E3Q53645807-7664F4A3-236E-4E89-83AE-AB239375FF0FQ55005321-006BDF1B-B581-4F8F-9114-9C09E4846AE1Q55364011-35500D45-CF11-4AD1-B860-20B6A3195810
P2860
Clinical Course of Oxaliplatin-Induced Neuropathy: Results From the Randomized Phase III Trial N08CB (Alliance).
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Clinical Course of Oxaliplatin ...... se III Trial N08CB (Alliance).
@ast
Clinical Course of Oxaliplatin ...... se III Trial N08CB (Alliance).
@en
type
label
Clinical Course of Oxaliplatin ...... se III Trial N08CB (Alliance).
@ast
Clinical Course of Oxaliplatin ...... se III Trial N08CB (Alliance).
@en
prefLabel
Clinical Course of Oxaliplatin ...... se III Trial N08CB (Alliance).
@ast
Clinical Course of Oxaliplatin ...... se III Trial N08CB (Alliance).
@en
P2093
P2860
P356
P1476
Clinical Course of Oxaliplatin ...... se III Trial N08CB (Alliance).
@en
P2093
Andreas S Beutler
Axel Grothey
Charles L Loprinzi
Deirdre R Pachman
Drew K Seisler
Ellen M L Smith
Jacqueline M Lafky
Kathryn J Ruddy
Lauren E Ta
Nina D Wagner-Johnston
P2860
P304
P356
10.1200/JCO.2014.58.8533
P407
P577
2015-08-17T00:00:00Z